Cambrian expands fibrosis pipeline
Drug Discovery World
JANUARY 13, 2023
Cambrian BioPharma has unveiled its latest pipeline company, Isterian Biotech. . The preclinical start-up is working towards the development of first-in-class small molecule inhibitors of transglutaminase 2 (TG2), one of the major crosslinking enzymes in the human body, which becomes more active during ageing, resulting in fibrotic diseases. . With age a chronic increase of crosslinked proteins occurs in the extracellular matrix (ECM).
Let's personalize your content